Undeterred by Ukrainian unrest, KCR acquires portfolio of clinical projects

By Zachary Brennan

- Last updated on GMT

Undeterred by Ukrainian unrest, KCR acquires new clinical projects

Related tags European union

European CRO KCR has acquired a portfolio of clinical projects from the Ukrainian CRO Axis Group thereby making the country the most important location for KCR in the region of the Commonwealth of Independent States (CIS).

With the integration of 15 AXIS projects and almost the entire clinical operations team, we consider KCR as one of the key players in Ukraine in regards to trials execution,​” said Mike Jagielski​, President and CEO of KCR. "Ukraine, being the second most populated country in the CIS region, presents a favorable market for conducting clinical studies​."

Tetyana Byelyayeva, General Manager for Ukraine and Georgia, at KCR added that the “political situation in the Eastern part of the country does not affect ongoing projects, neither any submission procedures. We conduct all studies according to timelines​.”

Other CROs seem similarly unfazed by the Ukrainian unrest, with Quintiles, PPD, Icon and Parexel all continuing trials in the country​.

KCR has had a registered subsidiary in Ukraine since 2007, with a team of 40 experienced specialists, and an office located in the heart of Kyiv. Important market drivers, according to the subsidiary, are submission requirements adjusted to the EU regulations as well as recent improvements to the regulatory framework regarding new rules on liability insurance as well as guidelines set for bioequivalence studies.

Ukraine has a well-developed system of medical institutions and universities, highly qualified investigators and more and more experienced sites which translates into effective patients recruitment​,” adds Jagielski.

In March, KCR expanded into the UK and Germany​ with new subsidiaries. The company now has a presence in 19 countries in Europe, as well as the US.

Jagielski also previously told us in an interview that mid-sized CROs have business model problems​, which he said hampers innovative development.

Related news

Show more

Related products

show more

Drug Solubility and the Need for Speed

Drug Solubility and the Need for Speed

Lonza Small Molecules | 28-Mar-2023 | Technical / White Paper

A growing number of new chemical entities are highly insoluble, leading to problems with bioavailability. Drug manufacturers therefore have to find ways...

Are You Prepared to Meet the New FDA Guidelines?

Are You Prepared to Meet the New FDA Guidelines?

Elligo Health Research® | 23-Mar-2023 | Insight Guide

On April 15, 2022, the U.S. Food and Drug Administration issued a new draft guidance to clinical research sponsors on creating a plan to enroll more participants...

ODM and CDASH in CRF design

ODM and CDASH in CRF design

Formedix | 10-Mar-2023 | Technical / White Paper

The lesser-known Operational Data Model (ODM) standard is often overlooked as it's not required by any regulators. So, why should you be interested...

4 Warning Signs Your Research Site Is in Trouble

4 Warning Signs Your Research Site Is in Trouble

Elligo Health Research® | 10-Mar-2023 | Insight Guide

You want your clinical research practice to be a success for your business and your patients, but how can you tell if it’s in trouble? Read this article...

Related suppliers

Follow us


View more